AU Patent

AU2017205690B2 — Controlled-release CNP agonists with increased NEP stability

Assigned to Ascendis Pharma Endocrinology Division AS · Expires 2022-04-28 · 4y expired

What this patent protects

The present invention relates to controlled-release CNP agonists having an at least 5-fold longer degradation half-life in an

USPTO Abstract

The present invention relates to controlled-release CNP agonists having an at least 5-fold longer degradation half-life in an

Drugs covered by this patent

Patent Metadata

Patent number: AU2017205690B2
Jurisdiction: AU
Classification: —
Expires: 2022-04-28
Drug substance claim: No
Drug product claim: No
Assignee: Ascendis Pharma Endocrinology Division AS
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.